| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
321,046 |
239,780 |
$20.78M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
257,029 |
186,838 |
$15.80M |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
133,722 |
93,721 |
$8.60M |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
69,144 |
17,523 |
$8.32M |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
97,984 |
27,675 |
$5.02M |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
39,952 |
29,584 |
$5.00M |
| 90935 |
Hemodialysis procedure with single evaluation by a physician |
27,376 |
3,315 |
$4.83M |
| 80053 |
Comprehensive metabolic panel |
293,891 |
195,889 |
$4.28M |
| 96367 |
|
13,266 |
7,730 |
$3.79M |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
59,414 |
44,629 |
$3.51M |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
53,172 |
35,156 |
$2.98M |
| 96361 |
Intravenous infusion, hydration; each additional hour |
63,179 |
45,620 |
$2.94M |
| 84703 |
|
151,325 |
108,642 |
$2.92M |
| G0378 |
Hospital observation service, per hour |
118,397 |
45,182 |
$2.83M |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
63,893 |
20,529 |
$2.61M |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
58,028 |
34,128 |
$2.30M |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
54,385 |
40,800 |
$2.17M |
| 70450 |
Computed tomography, head or brain; without contrast material |
40,311 |
29,109 |
$2.14M |
| 96375 |
Therapeutic injection; each additional sequential IV push |
135,597 |
83,567 |
$1.87M |
| J9271 |
Injection, pembrolizumab, 1 mg |
1,317 |
959 |
$1.85M |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
17,609 |
12,659 |
$1.56M |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
21,126 |
15,623 |
$1.52M |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
151,513 |
105,535 |
$1.36M |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
29,777 |
21,179 |
$1.34M |
| 77386 |
|
6,960 |
504 |
$1.30M |
| 71275 |
Computed tomographic angiography, chest, with contrast material |
11,706 |
8,561 |
$1.21M |
| 97161 |
|
15,103 |
12,498 |
$1.18M |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
24,335 |
18,040 |
$1.17M |
| 80048 |
Basic metabolic panel (calcium, ionized) |
140,748 |
90,232 |
$1.15M |
| 96413 |
Chemotherapy administration, intravenous infusion; up to 1 hour, single or initial substance |
15,317 |
8,164 |
$1.10M |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
33,213 |
23,814 |
$1.07M |
| 86900 |
|
32,617 |
23,331 |
$1.05M |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
87,007 |
53,310 |
$1.05M |
| 77412 |
|
7,006 |
653 |
$970K |
| 44970 |
|
1,045 |
827 |
$960K |
| J0885 |
Injection, epoetin alfa, (for non-esrd use), 1000 units |
11,591 |
1,153 |
$932K |
| 82947 |
|
121,149 |
42,581 |
$923K |
| 90999 |
Unlisted dialysis procedure, inpatient or outpatient |
4,096 |
324 |
$851K |
| 59025 |
Fetal non-stress test |
27,198 |
16,749 |
$851K |
| Q4081 |
Injection, epoetin alfa, 100 units (for esrd on dialysis) |
5,927 |
537 |
$795K |
| 84484 |
|
119,005 |
55,664 |
$754K |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
27,795 |
8,445 |
$738K |
| 01999 |
|
17,815 |
12,862 |
$723K |
| 95810 |
Polysomnography; sleep staging with 4 or more additional parameters |
2,060 |
1,567 |
$718K |
| A0431 |
Ambulance service, conventional air services, transport, one way (rotary wing) |
782 |
674 |
$692K |
| A9575 |
Injection, gadoterate meglumine, 0.1 ml |
5,979 |
4,417 |
$680K |
| 87636 |
Infectious agent detection by nucleic acid; SARS-CoV-2 and influenza virus types A and B |
59,707 |
44,580 |
$668K |
| 84702 |
|
30,742 |
19,401 |
$623K |
| 43239 |
Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple |
6,047 |
4,779 |
$607K |
| 47562 |
|
994 |
683 |
$577K |
| 92523 |
|
4,661 |
4,367 |
$563K |
| 81003 |
|
220,069 |
158,199 |
$546K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
11,898 |
8,659 |
$536K |
| 41899 |
Unlisted procedure, dentoalveolar structures |
2,933 |
2,626 |
$512K |
| J2505 |
Injection, pegfilgrastim, 6 mg |
1,149 |
814 |
$506K |
| A0426 |
Ambulance service, advanced life support, non-emergency transport, level 1 (als 1) |
6,566 |
5,033 |
$503K |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
4,542 |
2,910 |
$501K |
| D2930 |
Prefabricated stainless steel crown - primary tooth |
1,429 |
682 |
$493K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
373,912 |
238,433 |
$479K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
26,505 |
18,450 |
$473K |
| J9035 |
Injection, bevacizumab, 10 mg |
1,523 |
777 |
$460K |
| J1644 |
Injection, heparin sodium, per 1000 units |
33,435 |
5,634 |
$454K |
| 92526 |
|
11,900 |
4,354 |
$447K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
17,051 |
13,692 |
$433K |
| 70553 |
Magnetic resonance imaging, brain; without contrast material, followed by contrast material and further sequences |
5,194 |
3,920 |
$421K |
| 88305 |
Level IV - Surgical pathology, gross and microscopic examination |
20,561 |
12,662 |
$417K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
19,115 |
15,208 |
$407K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
24,202 |
17,746 |
$394K |
| 75574 |
|
4,503 |
3,063 |
$392K |
| 71046 |
Radiologic examination, chest; 2 views |
34,335 |
26,392 |
$388K |
| 58661 |
|
496 |
384 |
$382K |
| 85027 |
|
61,327 |
39,520 |
$379K |
| J1756 |
Injection, iron sucrose, 1 mg |
7,487 |
2,246 |
$365K |
| C1713 |
Anchor/screw for opposing bone-to-bone or soft tissue-to-bone (implantable) |
1,840 |
1,284 |
$358K |
| 87088 |
|
82,543 |
60,952 |
$356K |
| 97112 |
Therapeutic procedure, each 15 minutes; neuromuscular reeducation of movement, balance, coordination |
17,485 |
5,319 |
$355K |
| 70551 |
Magnetic resonance imaging, brain; without contrast material |
5,895 |
4,203 |
$340K |
| 84443 |
Thyroid stimulating hormone (TSH) |
46,812 |
33,921 |
$339K |
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
8,176 |
5,514 |
$336K |
| 96415 |
|
3,888 |
2,391 |
$327K |
| 54161 |
|
729 |
692 |
$314K |
| 96376 |
|
51,622 |
22,483 |
$314K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
5,674 |
4,110 |
$314K |
| J1745 |
Injection, infliximab, excludes biosimilar, 10 mg |
784 |
673 |
$312K |
| 49083 |
|
3,600 |
1,379 |
$300K |
| 83880 |
|
29,658 |
21,191 |
$290K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
21,452 |
17,393 |
$280K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
159,608 |
101,653 |
$279K |
| 71045 |
Radiologic examination, chest; single view |
109,978 |
77,929 |
$279K |
| 95811 |
|
826 |
600 |
$274K |
| 97165 |
|
3,922 |
3,148 |
$269K |
| 78815 |
Positron emission tomography (PET) for limited area imaging |
2,174 |
1,663 |
$265K |
| 36415 |
Collection of venous blood by venipuncture |
77,864 |
42,028 |
$264K |
| 95813 |
|
957 |
907 |
$258K |
| 84520 |
|
7,702 |
4,868 |
$252K |
| 85610 |
|
73,135 |
45,455 |
$250K |
| 45380 |
Colonoscopy, flexible; with biopsy, single or multiple |
2,332 |
1,784 |
$243K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
9,564 |
6,184 |
$242K |
| 10060 |
|
3,811 |
2,833 |
$239K |
| 76705 |
Ultrasound, abdominal, real time with image documentation; limited |
16,640 |
12,237 |
$239K |
| 97116 |
|
17,190 |
7,229 |
$238K |
| J2501 |
Injection, paricalcitol, 1 mcg |
11,744 |
779 |
$233K |
| 97164 |
|
2,964 |
2,614 |
$232K |
| 87651 |
Infectious agent detection by nucleic acid; Streptococcus, group A, amplified probe |
25,628 |
19,603 |
$228K |
| D7140 |
Extraction, erupted tooth or exposed root |
958 |
544 |
$227K |
| 80047 |
|
9,228 |
7,088 |
$226K |
| G0463 |
Hospital outpatient clinic visit for assessment and management of a patient |
10,675 |
6,285 |
$218K |
| 70491 |
|
2,286 |
1,755 |
$218K |
| 73610 |
|
11,631 |
8,343 |
$216K |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
60,725 |
32,542 |
$214K |
| 36561 |
|
564 |
409 |
$212K |
| 83970 |
|
5,758 |
3,932 |
$208K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
8,650 |
6,145 |
$208K |
| J3490 |
Unclassified drugs |
4,529 |
3,039 |
$204K |
| 78452 |
Myocardial perfusion imaging, tomographic (SPECT); multiple studies at rest and/or stress |
2,351 |
1,692 |
$196K |
| 70498 |
|
1,467 |
992 |
$195K |
| 97162 |
|
6,367 |
4,695 |
$193K |
| J9355 |
Injection, trastuzumab, excludes biosimilar, 10 mg |
527 |
236 |
$191K |
| J7030 |
Infusion, normal saline solution , 1000 cc |
159,596 |
96,978 |
$190K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
2,911 |
1,881 |
$189K |
| A9270 |
Non-covered item or service |
22,599 |
9,092 |
$184K |
| 76819 |
Fetal biophysical profile; without non-stress testing |
6,546 |
4,520 |
$182K |
| J0690 |
Injection, cefazolin sodium, 500 mg |
19,268 |
11,739 |
$173K |
| 77334 |
|
2,027 |
1,088 |
$169K |
| 76830 |
Ultrasound, transvaginal |
13,766 |
10,235 |
$169K |
| 86850 |
|
18,743 |
13,490 |
$168K |
| 97168 |
|
1,619 |
1,460 |
$168K |
| J1642 |
Injection, heparin sodium, (heparin lock flush), per 10 units |
18,027 |
9,017 |
$161K |
| 92587 |
|
3,971 |
3,079 |
$161K |
| 58571 |
|
118 |
73 |
$160K |
| C1769 |
Guide wire |
7,645 |
5,352 |
$159K |
| 92610 |
|
2,643 |
2,184 |
$159K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
3,287 |
2,623 |
$155K |
| 73130 |
|
9,434 |
6,592 |
$152K |
| 88185 |
|
2,739 |
1,317 |
$152K |
| 36430 |
|
5,005 |
2,832 |
$151K |
| 93971 |
|
9,103 |
6,849 |
$151K |
| 73630 |
|
13,099 |
9,202 |
$145K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
41,238 |
32,001 |
$145K |
| 80076 |
|
22,909 |
17,094 |
$143K |
| 97535 |
Self-care/home management training, each 15 minutes |
6,859 |
3,602 |
$141K |
| 76801 |
|
19,264 |
12,794 |
$140K |
| 97150 |
Therapeutic procedure(s), group (2 or more individuals) |
11,246 |
5,091 |
$137K |
| 97602 |
|
2,595 |
1,106 |
$133K |
| 92588 |
|
1,171 |
1,113 |
$133K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
41,379 |
32,174 |
$133K |
| 84100 |
|
16,555 |
9,658 |
$133K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
2,673 |
1,996 |
$132K |
| A0434 |
Specialty care transport (sct) |
755 |
492 |
$131K |
| 76770 |
|
4,533 |
3,450 |
$130K |
| Q5105 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for esrd on dialysis), 100 units |
6,050 |
518 |
$129K |
| J0610 |
Injection, calcium gluconate (fresenius kabi), per 10 ml |
692 |
333 |
$128K |
| 45385 |
Colonoscopy, flexible; with removal of tumor(s), polyp(s), or other lesion(s) |
968 |
717 |
$124K |
| 73564 |
|
11,083 |
7,853 |
$123K |
| J0897 |
Injection, denosumab, 1 mg |
1,088 |
924 |
$123K |
| 82803 |
|
7,166 |
5,151 |
$122K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
13,659 |
10,471 |
$121K |
| 76817 |
Ultrasound, pregnant uterus, real time with image documentation, transvaginal |
23,118 |
16,323 |
$120K |
| 82728 |
|
11,696 |
8,597 |
$119K |
| 86923 |
|
3,213 |
1,881 |
$117K |
| Q5106 |
Injection, epoetin alfa-epbx, biosimilar, (retacrit) (for non-esrd use), 1000 units |
4,584 |
613 |
$117K |
| J0485 |
Injection, belatacept, 1 mg |
1,048 |
507 |
$117K |
| 45378 |
Colonoscopy, flexible; diagnostic, including collection of specimen(s) |
534 |
416 |
$115K |
| J1439 |
Injection, ferric carboxymaltose, 1 mg |
741 |
461 |
$114K |
| J2506 |
Injection, pegfilgrastim, excludes biosimilar, 0.5 mg |
253 |
166 |
$113K |
| 84132 |
|
8,260 |
5,147 |
$110K |
| 77336 |
|
4,368 |
1,583 |
$109K |
| 83550 |
|
7,875 |
5,711 |
$108K |
| 36591 |
|
3,504 |
2,187 |
$106K |
| 70496 |
|
1,879 |
1,306 |
$105K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
3,606 |
3,033 |
$105K |
| 77295 |
|
375 |
249 |
$105K |
| 83540 |
|
10,325 |
7,493 |
$103K |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
118,914 |
75,823 |
$102K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
4,029 |
2,242 |
$101K |
| 82657 |
|
1,095 |
1,000 |
$101K |
| 87210 |
|
37,743 |
28,950 |
$100K |
| 97113 |
|
2,280 |
800 |
$98K |
| A0436 |
Rotary wing air mileage, per statute mile |
748 |
657 |
$97K |
| 93458 |
|
424 |
309 |
$96K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
3,037 |
2,240 |
$95K |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
6,012 |
4,202 |
$95K |
| 73140 |
|
4,092 |
2,954 |
$95K |
| 74018 |
|
7,744 |
5,713 |
$95K |
| Q9966 |
Low osmolar contrast material, 200-299 mg/ml iodine concentration, per ml |
3,998 |
3,095 |
$90K |
| 77290 |
|
658 |
437 |
$89K |
| 71260 |
Computed tomography, thorax, diagnostic; with contrast material |
5,378 |
3,940 |
$89K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
2,372 |
1,831 |
$88K |
| J7050 |
Infusion, normal saline solution, 250 cc |
40,520 |
20,385 |
$88K |
| 76536 |
|
2,084 |
1,600 |
$87K |
| 73030 |
|
9,367 |
6,544 |
$86K |
| P9040 |
Red blood cells, leukocytes reduced, irradiated, each unit |
1,065 |
622 |
$85K |
| 70310 |
|
1,798 |
1,562 |
$85K |
| 82274 |
|
4,232 |
3,175 |
$82K |
| 82565 |
|
15,396 |
10,964 |
$81K |
| 84436 |
|
1,783 |
1,360 |
$80K |
| J9263 |
Injection, oxaliplatin, 0.5 mg |
393 |
143 |
$79K |
| 97597 |
|
1,957 |
657 |
$79K |
| 97166 |
|
1,471 |
1,168 |
$77K |
| 85014 |
|
15,343 |
11,311 |
$76K |
| 52356 |
|
104 |
62 |
$76K |
| 93970 |
|
4,621 |
3,369 |
$76K |
| 73110 |
|
6,926 |
5,064 |
$74K |
| 89060 |
|
2,202 |
1,692 |
$74K |
| J2704 |
Injection, propofol, 10 mg |
31,100 |
23,550 |
$74K |
| 82731 |
|
1,027 |
838 |
$74K |
| 96402 |
|
1,441 |
1,239 |
$73K |
| 77066 |
Tomosynthesis, mammo |
1,894 |
1,375 |
$73K |
| J1200 |
Injection, diphenhydramine hcl, up to 50 mg |
33,117 |
20,756 |
$73K |
| 93976 |
|
4,155 |
3,164 |
$72K |
| J1442 |
Injection, filgrastim (g-csf), excludes biosimilars, 1 microgram |
1,814 |
496 |
$72K |
| 93017 |
|
2,757 |
2,052 |
$71K |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
29,300 |
21,258 |
$71K |
| 78306 |
|
1,028 |
749 |
$70K |
| 80197 |
|
6,718 |
3,447 |
$70K |
| P9047 |
Infusion, albumin (human), 25%, 50 ml |
1,275 |
527 |
$69K |
| J1453 |
Injection, fosaprepitant, 1 mg |
1,859 |
1,223 |
$69K |
| 73080 |
|
4,711 |
3,430 |
$68K |
| 76815 |
Ultrasound, pregnant uterus, real time with image documentation, limited |
12,473 |
9,511 |
$68K |
| 70486 |
|
3,288 |
2,382 |
$66K |
| J1561 |
Injection, immune globulin, (gamunex-c/gammaked), non-lyophilized (e.g., liquid), 500 mg |
295 |
187 |
$66K |
| 83735 |
|
58,822 |
38,072 |
$66K |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
22,969 |
16,135 |
$66K |
| 71250 |
|
3,762 |
2,654 |
$65K |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
59,756 |
43,719 |
$65K |
| J9395 |
Injection, fulvestrant, 25 mg |
351 |
300 |
$65K |
| 80061 |
Lipid panel |
30,949 |
22,822 |
$65K |
| 12001 |
|
4,054 |
3,037 |
$64K |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
5,086 |
1,422 |
$64K |
| 72148 |
Magnetic resonance imaging, lumbar spine; without contrast material |
1,499 |
1,081 |
$62K |
| J9299 |
Injection, nivolumab, 1 mg |
67 |
50 |
$60K |
| 85018 |
|
8,264 |
4,297 |
$59K |
| 96416 |
|
1,205 |
708 |
$59K |
| 86901 |
|
32,489 |
23,226 |
$59K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
39,860 |
25,702 |
$58K |
| 86833 |
|
1,062 |
773 |
$57K |
| J9312 |
Injection, rituximab, 10 mg |
211 |
102 |
$56K |
| C1788 |
Port, indwelling (implantable) |
602 |
442 |
$55K |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
40,576 |
27,214 |
$55K |
| 84156 |
|
7,705 |
5,294 |
$55K |
| J2997 |
Injection, alteplase recombinant, 1 mg |
852 |
547 |
$55K |
| 29125 |
|
2,471 |
1,890 |
$55K |
| 74230 |
|
686 |
543 |
$54K |
| 12011 |
|
3,816 |
2,855 |
$53K |
| 72131 |
|
2,694 |
2,019 |
$52K |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
2,754 |
1,959 |
$52K |
| 87497 |
|
2,683 |
1,666 |
$51K |
| 89050 |
|
2,132 |
1,397 |
$51K |
| 74183 |
|
1,411 |
1,022 |
$51K |
| 87070 |
|
8,475 |
6,168 |
$51K |
| 76642 |
|
2,393 |
1,724 |
$51K |
| 93308 |
|
1,040 |
762 |
$50K |
| 80074 |
|
1,813 |
1,404 |
$50K |
| 96368 |
|
2,360 |
1,604 |
$49K |
| 86832 |
|
1,112 |
801 |
$49K |
| 72100 |
|
7,390 |
5,492 |
$49K |
| 82247 |
|
2,599 |
1,683 |
$48K |
| 88307 |
|
3,996 |
2,615 |
$48K |
| 84112 |
|
405 |
351 |
$48K |
| 96523 |
|
4,109 |
3,207 |
$46K |
| 88304 |
|
4,181 |
2,942 |
$46K |
| C1894 |
Introducer/sheath, other than guiding, other than intracardiac electrophysiological, non-laser |
3,984 |
2,858 |
$45K |
| 0100U |
|
1,426 |
1,046 |
$45K |
| 97014 |
|
11,889 |
3,619 |
$44K |
| 76870 |
|
2,721 |
1,996 |
$42K |
| 73502 |
|
4,864 |
3,689 |
$41K |
| 96377 |
|
509 |
380 |
$41K |
| 83690 |
|
79,181 |
56,248 |
$41K |
| 74021 |
|
2,565 |
2,047 |
$39K |
| J1170 |
Injection, hydromorphone, up to 4 mg |
23,068 |
10,936 |
$39K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
5,120 |
4,344 |
$39K |
| 78264 |
|
337 |
254 |
$38K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
26,906 |
19,114 |
$38K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
29,962 |
21,969 |
$38K |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
1,854 |
1,092 |
$37K |
| 77300 |
|
1,333 |
933 |
$36K |
| J2370 |
Injection, phenylephrine hcl, up to 1 ml |
6,888 |
4,604 |
$36K |
| 93505 |
|
116 |
91 |
$35K |
| 72197 |
|
558 |
421 |
$35K |
| G8987 |
Self care functional limitation, current status, at therapy episode outset and at reporting intervals |
1,164 |
477 |
$34K |
| 73090 |
|
5,781 |
4,095 |
$34K |
| 73100 |
|
1,900 |
1,271 |
$33K |
| 52332 |
|
231 |
159 |
$33K |
| 84460 |
|
1,683 |
1,088 |
$33K |
| 92950 |
|
632 |
355 |
$33K |
| 95716 |
|
835 |
574 |
$33K |
| G8988 |
Self care functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,237 |
509 |
$33K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
1,167 |
790 |
$32K |
| 95816 |
|
948 |
660 |
$32K |
| 84439 |
|
18,453 |
13,506 |
$32K |
| J3370 |
Injection, vancomycin hcl, 500 mg |
3,952 |
1,810 |
$32K |
| 92650 |
|
1,079 |
756 |
$32K |
| 73590 |
|
5,484 |
3,908 |
$31K |
| 73660 |
|
1,487 |
1,101 |
$31K |
| J0561 |
Injection, penicillin g benzathine, 100,000 units |
921 |
720 |
$30K |
| 87340 |
|
4,250 |
3,389 |
$30K |
| 85730 |
|
33,447 |
24,211 |
$30K |
| 84145 |
|
4,649 |
3,265 |
$30K |
| 72141 |
|
1,096 |
796 |
$30K |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
1,911 |
1,114 |
$30K |
| J0360 |
Injection, hydralazine hcl, up to 20 mg |
4,409 |
2,799 |
$30K |
| 87186 |
|
23,789 |
17,163 |
$29K |
| 80177 |
|
3,354 |
2,206 |
$29K |
| 72040 |
|
4,262 |
3,173 |
$29K |
| 86304 |
|
778 |
595 |
$29K |
| 76010 |
|
578 |
433 |
$29K |
| 77280 |
|
222 |
155 |
$29K |
| 86706 |
|
2,435 |
1,834 |
$29K |
| 70544 |
|
2,137 |
1,373 |
$28K |
| 74240 |
|
542 |
439 |
$28K |
| 69200 |
|
400 |
312 |
$28K |
| 12002 |
|
2,069 |
1,470 |
$27K |
| 82040 |
|
226 |
171 |
$27K |
| 84450 |
|
758 |
559 |
$27K |
| 50590 |
|
66 |
50 |
$26K |
| 73070 |
|
1,626 |
1,057 |
$26K |
| 96401 |
|
1,666 |
976 |
$26K |
| 66984 |
Extracapsular cataract removal with insertion of intraocular lens prosthesis |
404 |
257 |
$25K |
| 73700 |
|
1,292 |
924 |
$25K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
321 |
282 |
$24K |
| J3380 |
Injection, vedolizumab, intravenous, 1 mg |
100 |
85 |
$24K |
| 85097 |
|
538 |
337 |
$24K |
| 76641 |
|
668 |
448 |
$24K |
| 87653 |
|
1,673 |
1,412 |
$23K |
| 73552 |
|
2,194 |
1,633 |
$23K |
| 82607 |
|
11,569 |
8,670 |
$23K |
| G0121 |
Colorectal cancer screening; colonoscopy on individual not meeting criteria for high risk |
72 |
57 |
$23K |
| 87040 |
|
11,543 |
5,982 |
$22K |
| 77080 |
|
999 |
776 |
$22K |
| 97163 |
|
799 |
564 |
$22K |
| 87205 |
|
7,644 |
5,088 |
$22K |
| 83605 |
|
13,737 |
8,724 |
$22K |
| Q5107 |
Injection, bevacizumab-awwb, biosimilar, (mvasi), 10 mg |
36 |
15 |
$22K |
| 74022 |
|
4,697 |
3,631 |
$22K |
| 76805 |
Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation |
368 |
305 |
$22K |
| 99152 |
|
3,344 |
2,514 |
$21K |
| J7070 |
Infusion, d5w, 1000 cc |
30,204 |
15,486 |
$21K |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
96,368 |
63,560 |
$21K |
| 69209 |
|
316 |
241 |
$21K |
| 36592 |
|
867 |
459 |
$20K |
| J9310 |
Injection, rituximab, 100 mg |
49 |
12 |
$20K |
| 86140 |
|
21,519 |
15,523 |
$20K |
| 71101 |
|
2,594 |
1,949 |
$20K |
| 87799 |
|
2,418 |
1,596 |
$20K |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
13,118 |
9,210 |
$20K |
| 29515 |
|
1,161 |
898 |
$20K |
| 92508 |
Group treatment of speech, language, voice, communication, and/or auditory processing disorder |
894 |
345 |
$20K |
| 87506 |
|
1,392 |
1,074 |
$19K |
| D2392 |
Resin-based composite - two surfaces, posterior, primary or permanent |
32 |
27 |
$19K |
| 82784 |
|
3,265 |
2,332 |
$19K |
| 82310 |
|
143 |
107 |
$19K |
| 84295 |
|
2,041 |
1,509 |
$19K |
| 86922 |
|
1,513 |
846 |
$19K |
| 96409 |
|
1,050 |
773 |
$19K |
| 77301 |
|
49 |
36 |
$19K |
| C1781 |
Mesh (implantable) |
607 |
415 |
$19K |
| 29105 |
|
626 |
495 |
$18K |
| A0425 |
Ground mileage, per statute mile |
17,297 |
12,390 |
$18K |
| C1758 |
Catheter, ureteral |
1,698 |
1,099 |
$18K |
| 87420 |
|
3,391 |
2,891 |
$18K |
| 73562 |
|
2,519 |
1,703 |
$18K |
| 82746 |
|
6,243 |
4,660 |
$18K |
| 82533 |
|
1,369 |
941 |
$18K |
| D2330 |
|
209 |
131 |
$18K |
| 88341 |
|
1,789 |
1,083 |
$18K |
| 70360 |
|
1,181 |
929 |
$17K |
| C1751 |
Catheter, infusion, inserted peripherally, centrally or midline (other than hemodialysis) |
555 |
408 |
$17K |
| C1725 |
Catheter, transluminal angioplasty, non-laser (may include guidance, infusion/perfusion capability) |
1,045 |
658 |
$17K |
| 93303 |
Transthoracic echocardiography for congenital cardiac anomalies, follow-up or limited study |
109 |
97 |
$17K |
| 38222 |
|
166 |
98 |
$17K |
| 54304 |
|
14 |
14 |
$17K |
| 84481 |
|
2,655 |
2,063 |
$16K |
| 82330 |
|
1,832 |
1,330 |
$16K |
| 76937 |
|
1,407 |
1,030 |
$16K |
| 96417 |
|
4,503 |
2,870 |
$15K |
| 77072 |
|
589 |
406 |
$15K |
| J9267 |
Injection, paclitaxel, 1 mg |
1,192 |
570 |
$15K |
| 82010 |
|
4,841 |
3,458 |
$15K |
| 43235 |
|
77 |
65 |
$14K |
| 94010 |
|
275 |
225 |
$14K |
| 85379 |
|
21,129 |
15,446 |
$14K |
| 84075 |
|
68 |
53 |
$14K |
| 84155 |
|
44 |
39 |
$14K |
| 99153 |
Mod sedat endo service >5yrs |
2,262 |
1,666 |
$14K |
| 76775 |
|
724 |
541 |
$14K |
| 24640 |
|
154 |
126 |
$14K |
| 70487 |
|
112 |
98 |
$13K |
| 80143 |
|
6,996 |
4,898 |
$13K |
| 86828 |
|
689 |
517 |
$13K |
| 77065 |
Tomosynthesis, mammo |
611 |
441 |
$13K |
| J2060 |
Injection, lorazepam, 2 mg |
18,280 |
11,456 |
$13K |
| 87077 |
|
22,850 |
16,010 |
$13K |
| 72156 |
|
272 |
181 |
$13K |
| 94660 |
|
641 |
358 |
$12K |
| 72158 |
|
424 |
306 |
$12K |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
12,021 |
8,237 |
$12K |
| 73560 |
|
884 |
604 |
$12K |
| 94761 |
|
2,095 |
1,334 |
$12K |
| 88173 |
|
283 |
189 |
$12K |
| 74178 |
|
170 |
125 |
$11K |
| 73060 |
|
2,114 |
1,553 |
$11K |
| C2617 |
Stent, non-coronary, temporary, without delivery system |
1,298 |
899 |
$11K |
| D3220 |
Therapeutic pulpotomy (excluding final restoration) - removal of pulp coronal to the dentinocemental junction |
422 |
234 |
$11K |
| 86038 |
|
1,493 |
1,175 |
$11K |
| 85049 |
|
3,202 |
2,235 |
$11K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
275 |
217 |
$11K |
| 70547 |
|
1,492 |
962 |
$11K |
| 73721 |
Magnetic resonance imaging, any joint of lower extremity; without contrast material |
230 |
153 |
$11K |
| C1729 |
Catheter, drainage |
2,532 |
1,500 |
$10K |
| J2469 |
Injection, palonosetron hcl, 25 mcg |
1,205 |
716 |
$10K |
| 83615 |
|
4,634 |
3,375 |
$10K |
| 93798 |
|
310 |
48 |
$10K |
| J1815 |
Injection, insulin, per 5 units |
23,349 |
6,589 |
$10K |
| 83020 |
|
1,277 |
961 |
$10K |
| 86835 |
|
298 |
209 |
$10K |
| C1887 |
Catheter, guiding (may include infusion/perfusion capability) |
756 |
522 |
$10K |
| 19083 |
|
13 |
12 |
$10K |
| 70481 |
|
45 |
41 |
$9K |
| 77001 |
|
1,279 |
934 |
$9K |
| 92522 |
|
71 |
71 |
$9K |
| G8982 |
Changing & maintaining body position functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
501 |
170 |
$9K |
| 16020 |
|
600 |
413 |
$9K |
| 82550 |
|
14,348 |
9,847 |
$9K |
| 77470 |
|
36 |
26 |
$9K |
| 77387 |
|
1,558 |
176 |
$9K |
| 96411 |
|
1,323 |
932 |
$8K |
| 97750 |
|
469 |
364 |
$8K |
| 78582 |
|
172 |
121 |
$8K |
| 96450 |
|
145 |
115 |
$8K |
| G8981 |
Changing & maintaining body position functional limitation, current status, at therapy episode outset and at reporting intervals |
451 |
149 |
$8K |
| 81001 |
|
21,868 |
15,959 |
$8K |
| 31624 |
|
78 |
57 |
$8K |
| 88312 |
|
7,821 |
5,206 |
$8K |
| 99215 |
Prolong outpt/office vis |
267 |
228 |
$8K |
| 86834 |
|
298 |
209 |
$8K |
| 87631 |
|
244 |
190 |
$8K |
| 87075 |
|
2,863 |
1,995 |
$8K |
| 95951 |
|
608 |
240 |
$7K |
| 88342 |
|
3,103 |
2,083 |
$7K |
| J1610 |
Injection, glucagon hydrochloride, per 1 mg |
357 |
264 |
$7K |
| 81025 |
|
16,202 |
12,088 |
$7K |
| 87081 |
|
7,876 |
6,268 |
$7K |
| 64450 |
|
159 |
112 |
$7K |
| 73000 |
|
621 |
460 |
$7K |
| 92567 |
|
1,246 |
1,188 |
$7K |
| J9045 |
Injection, carboplatin, 50 mg |
884 |
600 |
$7K |
| 62328 |
|
42 |
39 |
$7K |
| 76857 |
|
3,894 |
2,967 |
$7K |
| D2391 |
Resin-based composite - one surface, posterior, primary or permanent |
126 |
59 |
$7K |
| 87015 |
|
3,038 |
2,053 |
$7K |
| 97022 |
|
639 |
182 |
$7K |
| 92579 |
|
688 |
660 |
$7K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
7,066 |
4,821 |
$7K |
| 86403 |
|
1,233 |
1,011 |
$7K |
| 93325 |
|
1,612 |
1,272 |
$7K |
| 78226 |
|
110 |
73 |
$7K |
| 76882 |
|
248 |
191 |
$7K |
| 88112 |
|
1,166 |
791 |
$7K |
| 0450 |
Emergency room services |
199 |
179 |
$6K |
| J0702 |
Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg |
471 |
256 |
$6K |
| 85652 |
|
13,819 |
10,430 |
$6K |
| 73523 |
|
1,055 |
687 |
$6K |
| 84681 |
|
335 |
284 |
$6K |
| 93880 |
|
728 |
540 |
$6K |
| J2710 |
Injection, neostigmine methylsulfate, up to 0.5 mg |
3,009 |
2,433 |
$6K |
| 74181 |
|
196 |
138 |
$6K |
| 82077 |
|
10,105 |
6,834 |
$6K |
| A9552 |
Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries |
2,326 |
1,799 |
$6K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
8,155 |
6,209 |
$6K |
| 87102 |
|
1,265 |
888 |
$6K |
| 72128 |
|
852 |
643 |
$6K |
| 90715 |
|
6,402 |
4,629 |
$6K |
| 93320 |
|
552 |
446 |
$6K |
| 90686 |
|
2,344 |
1,705 |
$6K |
| A9500 |
Technetium tc-99m sestamibi, diagnostic, per study dose |
2,599 |
1,752 |
$6K |
| J2800 |
Injection, methocarbamol, up to 10 ml |
3,564 |
2,152 |
$6K |
| 29130 |
|
746 |
573 |
$6K |
| 36590 |
|
51 |
40 |
$6K |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
227 |
209 |
$6K |
| 92557 |
|
403 |
366 |
$5K |
| J3475 |
Injection, magnesium sulfate, per 500 mg |
5,163 |
3,210 |
$5K |
| 10061 |
|
74 |
56 |
$5K |
| 87529 |
|
640 |
473 |
$5K |
| 87116 |
|
1,318 |
867 |
$5K |
| 82435 |
|
657 |
497 |
$5K |
| 87624 |
Infectious agent detection by nucleic acid; human papillomavirus (HPV), high-risk types |
281 |
241 |
$5K |
| 82374 |
|
17 |
14 |
$5K |
| 86334 |
|
721 |
553 |
$5K |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
9,860 |
5,766 |
$5K |
| D1310 |
|
396 |
364 |
$5K |
| 82108 |
|
111 |
86 |
$5K |
| 72072 |
|
2,039 |
1,524 |
$5K |
| C1726 |
Catheter, balloon dilatation, non-vascular |
46 |
37 |
$5K |
| P9037 |
Platelets, pheresis, leukocytes reduced, irradiated, each unit |
53 |
29 |
$5K |
| 88313 |
|
4,500 |
2,981 |
$5K |
| 87206 |
|
1,306 |
857 |
$5K |
| 80202 |
|
686 |
248 |
$5K |
| 51702 |
|
1,553 |
1,041 |
$5K |
| 43762 |
|
590 |
383 |
$5K |
| 73620 |
|
495 |
333 |
$5K |
| 84403 |
|
1,037 |
847 |
$4K |
| 86480 |
|
515 |
370 |
$4K |
| 95806 |
|
122 |
108 |
$4K |
| 58558 |
|
30 |
25 |
$4K |
| 74174 |
|
14 |
12 |
$4K |
| 94760 |
|
3,676 |
2,187 |
$4K |
| 80164 |
|
2,676 |
1,928 |
$4K |
| J0330 |
Injection, succinylcholine chloride, up to 20 mg |
1,544 |
1,116 |
$4K |
| J2360 |
Injection, orphenadrine citrate, up to 60 mg |
15,064 |
10,557 |
$4K |
| J2543 |
Injection, piperacillin sodium/tazobactam sodium, 1 gram/0.125 grams (1.125 grams) |
8,381 |
3,207 |
$4K |
| G1010 |
Clinical decision support mechanism stanson, as defined by the medicare appropriate use criteria program |
2,137 |
1,172 |
$4K |
| 80185 |
|
960 |
632 |
$4K |
| 73200 |
|
280 |
201 |
$4K |
| 84153 |
|
1,601 |
1,288 |
$4K |
| 59050 |
|
424 |
332 |
$4K |
| J2765 |
Injection, metoclopramide hcl, up to 10 mg |
15,781 |
10,850 |
$4K |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
11,588 |
4,616 |
$4K |
| J0780 |
Injection, prochlorperazine, up to 10 mg |
7,303 |
5,197 |
$4K |
| 74246 |
|
69 |
55 |
$3K |
| 87798 |
Infectious agent detection by nucleic acid; not otherwise specified, amplified probe, each organism |
207 |
144 |
$3K |
| 82378 |
|
1,965 |
1,418 |
$3K |
| 86592 |
|
4,271 |
3,489 |
$3K |
| J2920 |
Injection, methylprednisolone sodium succinate, up to 40 mg |
5,651 |
2,404 |
$3K |
| 95700 |
|
718 |
678 |
$3K |
| 86300 |
|
1,287 |
946 |
$3K |
| 72195 |
|
42 |
25 |
$3K |
| 82140 |
|
3,186 |
2,032 |
$3K |
| 83883 |
|
384 |
291 |
$3K |
| 77338 |
|
66 |
47 |
$3K |
| 43259 |
|
138 |
115 |
$3K |
| 84479 |
|
81 |
71 |
$3K |
| J2785 |
Injection, regadenoson, 0.1 mg |
2,052 |
1,468 |
$3K |
| 85045 |
|
3,937 |
2,593 |
$3K |
| 78227 |
|
47 |
26 |
$3K |
| 72192 |
|
78 |
64 |
$3K |
| J1953 |
Injection, levetiracetam, 10 mg |
1,768 |
1,007 |
$3K |
| 25605 |
|
85 |
66 |
$3K |
| 95819 |
|
72 |
63 |
$3K |
| G8980 |
Mobility: walking & moving around functional limitation, discharge status, at discharge from therapy or to end reporting |
226 |
203 |
$3K |
| 86870 |
|
121 |
76 |
$3K |
| 87522 |
Neg quan hep c or qual rna |
140 |
113 |
$3K |
| 94762 |
|
484 |
305 |
$3K |
| 72157 |
|
99 |
75 |
$3K |
| J1940 |
Injection, furosemide, up to 20 mg |
4,812 |
2,454 |
$3K |
| 10080 |
|
39 |
26 |
$3K |
| C9113 |
Injection, pantoprazole sodium, per vial |
15,269 |
7,906 |
$3K |
| 51701 |
|
2,601 |
2,082 |
$3K |
| L3908 |
Wrist hand orthosis, wrist extension control cock-up, non molded, prefabricated, off-the-shelf |
58 |
54 |
$3K |
| 84146 |
|
386 |
326 |
$3K |
| Q9957 |
Injection, perflutren lipid microspheres, per ml |
243 |
183 |
$3K |
| 86803 |
|
1,990 |
1,688 |
$3K |
| 85384 |
|
1,112 |
868 |
$3K |
| 82785 |
|
482 |
409 |
$3K |
| 31500 |
|
167 |
115 |
$2K |
| M0239 |
Intravenous infusion, bamlanivimab-xxxx, includes infusion and post administration monitoring |
47 |
42 |
$2K |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
326 |
300 |
$2K |
| 56420 |
|
28 |
12 |
$2K |
| G0238 |
Therapeutic procedures to improve respiratory function, other than described by g0237, one on one, face to face, per 15 minutes (includes monitoring) |
251 |
62 |
$2K |
| 85347 |
|
615 |
312 |
$2K |
| 82670 |
|
260 |
225 |
$2K |
| M0245 |
Intravenous infusion, bamlanivimab and etesevimab, includes infusion and post administration monitoring |
18 |
16 |
$2K |
| 70250 |
|
192 |
155 |
$2K |
| 82553 |
|
328 |
246 |
$2K |
| G0257 |
Unscheduled or emergency dialysis treatment for an esrd patient in a hospital outpatient department that is not certified as an esrd facility |
492 |
267 |
$2K |
| J0744 |
Injection, ciprofloxacin for intravenous infusion, 200 mg |
1,319 |
754 |
$2K |
| J1580 |
Injection, garamycin, gentamicin, up to 80 mg |
1,014 |
641 |
$2K |
| 83630 |
|
247 |
197 |
$2K |
| A9581 |
Injection, gadoxetate disodium, 1 ml |
50 |
39 |
$2K |
| 84550 |
|
5,878 |
4,299 |
$2K |
| 83525 |
|
1,107 |
895 |
$2K |
| 82105 |
|
613 |
491 |
$2K |
| 84157 |
|
1,387 |
1,057 |
$2K |
| 62270 |
|
93 |
75 |
$2K |
| A0429 |
Ambulance service, basic life support, emergency transport (bls-emergency) |
14 |
14 |
$2K |
| 86003 |
|
499 |
300 |
$2K |
| D1206 |
Topical application of fluoride varnish |
162 |
152 |
$2K |
| 88184 |
|
1,982 |
1,315 |
$2K |
| 84466 |
|
1,706 |
1,343 |
$2K |
| J0456 |
Injection, azithromycin, 500 mg |
2,061 |
1,195 |
$2K |
| 80195 |
|
291 |
134 |
$2K |
| 87661 |
Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe |
365 |
327 |
$2K |
| J3105 |
Injection, terbutaline sulfate, up to 1 mg |
282 |
237 |
$2K |
| 87807 |
|
170 |
153 |
$2K |
| 86762 |
|
1,478 |
1,216 |
$2K |
| 12013 |
|
215 |
173 |
$2K |
| J3486 |
Injection, ziprasidone mesylate, 10 mg |
1,787 |
1,110 |
$2K |
| 90670 |
|
421 |
241 |
$2K |
| 90732 |
|
52 |
25 |
$2K |
| J0171 |
Injection, adrenalin, epinephrine, 0.1 mg |
1,455 |
957 |
$2K |
| 82945 |
|
1,143 |
918 |
$2K |
| 72170 |
|
818 |
591 |
$2K |
| J3480 |
Injection, potassium chloride, per 2 meq |
3,868 |
2,064 |
$2K |
| 82570 |
|
7,873 |
5,666 |
$2K |
| J0692 |
Injection, cefepime hydrochloride, 500 mg |
3,187 |
1,346 |
$2K |
| 82627 |
|
97 |
92 |
$2K |
| D1120 |
Prophylaxis - child |
392 |
363 |
$2K |
| 86665 |
|
487 |
345 |
$2K |
| D1330 |
|
327 |
306 |
$1K |
| 73600 |
|
306 |
212 |
$1K |
| C8929 |
Transthoracic echocardiography with contrast, or without contrast followed by with contrast, real-time with image documentation (2d), includes m-mode recording, when performed, complete, with spectral doppler echocardiography, and with color flow doppler echocardiography |
44 |
42 |
$1K |
| J0461 |
Injection, atropine sulfate, 0.01 mg |
166 |
105 |
$1K |
| 94729 |
|
308 |
258 |
$1K |
| 87449 |
|
1,449 |
1,093 |
$1K |
| 74019 |
|
245 |
214 |
$1K |
| 82024 |
|
224 |
203 |
$1K |
| J9250 |
Methotrexate sodium, 5 mg |
384 |
221 |
$1K |
| G0008 |
Administration of influenza virus vaccine |
321 |
254 |
$1K |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
68 |
54 |
$1K |
| A9541 |
Technetium tc-99m sulfur colloid, diagnostic, per study dose, up to 20 millicuries |
469 |
340 |
$1K |
| 82232 |
|
165 |
130 |
$1K |
| 87324 |
|
1,359 |
1,016 |
$1K |
| 92611 |
|
565 |
450 |
$1K |
| 82248 |
|
2,941 |
2,023 |
$1K |
| 87505 |
|
304 |
236 |
$1K |
| 97010 |
|
547 |
255 |
$1K |
| 94726 |
|
207 |
171 |
$1K |
| OP250 |
|
250 |
144 |
$1K |
| 82365 |
|
171 |
88 |
$1K |
| J0207 |
Injection, amifostine, 500 mg |
42 |
27 |
$997.04 |
| 73120 |
|
142 |
104 |
$994.61 |
| A9503 |
Technetium tc-99m medronate, diagnostic, per study dose, up to 30 millicuries |
980 |
711 |
$979.73 |
| 80179 |
|
6,828 |
4,839 |
$947.30 |
| 86880 |
|
15 |
14 |
$938.87 |
| 86787 |
|
639 |
433 |
$935.57 |
| 43760 |
|
16 |
13 |
$923.49 |
| 87184 |
|
1,852 |
1,340 |
$907.26 |
| 77012 |
|
821 |
509 |
$903.96 |
| S0028 |
Injection, famotidine, 20 mg |
1,283 |
766 |
$878.29 |
| 72084 |
|
34 |
26 |
$875.08 |
| 87536 |
|
46 |
30 |
$854.46 |
| 88360 |
|
534 |
276 |
$848.97 |
| 97533 |
|
1,031 |
511 |
$835.08 |
| 70490 |
|
21 |
13 |
$821.95 |
| A4216 |
Sterile water, saline and/or dextrose, diluent/flush, 10 ml |
14 |
12 |
$820.49 |
| C9290 |
Injection, bupivacaine liposome, 1 mg |
1,132 |
832 |
$801.83 |
| J9070 |
Cyclophosphamide, 100 mg |
71 |
27 |
$800.55 |
| J1630 |
Injection, haloperidol, up to 5 mg |
2,101 |
1,380 |
$796.88 |
| 87252 |
|
121 |
97 |
$787.96 |
| 83002 |
|
650 |
572 |
$786.20 |
| 87634 |
|
789 |
689 |
$769.31 |
| P9046 |
Infusion, albumin (human), 25%, 20 ml |
84 |
39 |
$750.26 |
| 84134 |
|
580 |
429 |
$719.43 |
| 36593 |
|
31 |
25 |
$691.81 |
| J3420 |
Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg |
1,288 |
949 |
$688.63 |
| 88311 |
|
937 |
614 |
$687.72 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
2,126 |
1,408 |
$677.66 |
| L1830 |
Knee orthosis, immobilizer, canvas longitudinal, prefabricated, off-the-shelf |
17 |
13 |
$672.91 |
| 80162 |
|
116 |
83 |
$672.73 |
| J0640 |
Injection, leucovorin calcium, per 50 mg |
871 |
403 |
$642.73 |
| 76942 |
|
250 |
144 |
$633.31 |
| G0148 |
Screening cytopathology smears, cervical or vaginal, performed by automated system with manual rescreening |
236 |
208 |
$616.67 |
| 70480 |
|
37 |
28 |
$597.89 |
| A9540 |
Technetium tc-99m macroaggregated albumin, diagnostic, per study dose, up to 10 millicuries |
397 |
272 |
$570.69 |
| 83001 |
|
763 |
668 |
$566.69 |
| G0279 |
Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066) |
428 |
322 |
$557.78 |
| G0379 |
Direct admission of patient for hospital observation care |
448 |
388 |
$556.66 |
| 87181 |
|
397 |
272 |
$549.78 |
| 82150 |
|
2,153 |
1,593 |
$547.69 |
| 87147 |
|
2,930 |
2,223 |
$540.50 |
| J1950 |
Injection, leuprolide acetate (for depot suspension), per 3.75 mg |
13 |
12 |
$537.61 |
| 72080 |
|
18 |
14 |
$533.35 |
| J9190 |
Injection, fluorouracil, 500 mg |
776 |
394 |
$522.71 |
| 80156 |
|
251 |
213 |
$506.76 |
| 87046 |
|
456 |
231 |
$490.46 |
| 83521 |
|
79 |
37 |
$487.72 |
| 83516 |
|
937 |
606 |
$474.17 |
| J7042 |
5% dextrose/normal saline (500 ml = 1 unit) |
2,089 |
1,399 |
$462.85 |
| 90714 |
|
192 |
133 |
$462.68 |
| 86376 |
|
697 |
580 |
$458.66 |
| L1906 |
Ankle foot orthosis, multiligamentous ankle support, prefabricated, off-the-shelf |
15 |
13 |
$448.30 |
| 85460 |
|
29 |
26 |
$439.01 |
| 94150 |
|
244 |
200 |
$437.25 |
| 80184 |
|
117 |
90 |
$395.03 |
| 72146 |
|
52 |
44 |
$390.46 |
| 82043 |
|
2,325 |
1,897 |
$388.69 |
| G8991 |
Other physical or occupational therapy primary functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
65 |
27 |
$388.22 |
| 82575 |
|
15 |
13 |
$364.03 |
| 87641 |
|
145 |
120 |
$361.30 |
| 76981 |
|
13 |
13 |
$358.60 |
| 80178 |
|
30 |
26 |
$352.84 |
| G8990 |
Other physical or occupational therapy primary functional limitation, current status, at therapy episode outset and at reporting intervals |
61 |
27 |
$344.30 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
246 |
194 |
$341.82 |
| A9567 |
Technetium tc-99m pentetate, diagnostic, aerosol, per study dose, up to 75 millicuries |
121 |
92 |
$341.39 |
| J2272 |
Injection, morphine sulfate (fresenius kabi), not therapeutically equivalent to j2270, up to 10 mg |
173 |
130 |
$336.69 |
| 87045 |
|
294 |
231 |
$336.58 |
| 95713 |
|
27 |
18 |
$332.40 |
| 10120 |
|
18 |
15 |
$322.28 |
| 93321 |
|
695 |
536 |
$317.13 |
| 77062 |
|
922 |
616 |
$316.42 |
| 86800 |
|
246 |
195 |
$309.44 |
| 86352 |
|
89 |
67 |
$303.76 |
| J3411 |
Injection, thiamine hcl, 100 mg |
1,145 |
735 |
$297.87 |
| 82397 |
|
125 |
115 |
$266.41 |
| 49465 |
|
102 |
82 |
$263.68 |
| J0290 |
Injection, ampicillin sodium, 500 mg |
31 |
15 |
$259.43 |
| 86364 |
|
431 |
249 |
$258.27 |
| 11730 |
|
13 |
13 |
$256.33 |
| G0500 |
Moderate sedation services provided by the same physician or other qualified health care professional performing a gastrointestinal endoscopic service that sedation supports, requiring the presence of an independent trained observer to assist in the monitoring of the patient's level of consciousness and physiological status; initial 15 minutes of intra-service time; patient age 5 years or older (additional time may be reported with 99153, as appropriate) |
89 |
64 |
$216.47 |
| J2310 |
Injection, naloxone hydrochloride, per 1 mg |
147 |
102 |
$214.55 |
| 88142 |
|
75 |
67 |
$205.65 |
| 86645 |
|
341 |
288 |
$201.39 |
| 84480 |
|
869 |
687 |
$199.54 |
| 0042T |
|
18 |
16 |
$192.82 |
| 87640 |
|
119 |
97 |
$188.95 |
| 82950 |
|
140 |
127 |
$184.25 |
| 85007 |
|
2,386 |
1,742 |
$178.69 |
| J7512 |
Prednisone, immediate release or delayed release, oral, 1 mg |
9,987 |
6,732 |
$178.04 |
| J7121 |
5% dextrose in lactated ringers infusion, up to 1000 cc |
569 |
403 |
$173.54 |
| M0220 |
Injection, tixagevimab and cilgavimab, for the pre-exposure prophylaxis only, for certain adults and pediatric individuals (12 years of age and older weighing at least 40kg) with no known sars-cov-2 exposure, who either have moderate to severely compromised immune systems or for whom vaccination with any available covid-19 vaccine is not recommended due to a history of severe adverse reaction to a covid-19 vaccine(s) and/or covid-19 vaccine component(s), includes injection and post administration monitoring |
27 |
19 |
$165.79 |
| 85060 |
|
72 |
52 |
$159.21 |
| 82977 |
|
1,222 |
702 |
$155.85 |
| 86769 |
|
226 |
189 |
$153.28 |
| 86301 |
|
80 |
63 |
$153.17 |
| 72220 |
|
31 |
25 |
$139.80 |
| J9370 |
Vincristine sulfate, 1 mg |
1,031 |
703 |
$139.00 |
| V2632 |
Posterior chamber intraocular lens |
189 |
103 |
$138.66 |
| 97129 |
|
145 |
24 |
$136.30 |
| J1790 |
Injection, droperidol, up to 5 mg |
3,316 |
2,245 |
$132.83 |
| 86644 |
|
419 |
304 |
$129.69 |
| 88302 |
|
542 |
328 |
$114.16 |
| 77003 |
|
40 |
37 |
$110.68 |
| 94200 |
|
50 |
41 |
$108.14 |
| 86430 |
|
448 |
348 |
$102.00 |
| 85246 |
|
16 |
12 |
$96.92 |
| 87899 |
|
608 |
354 |
$96.47 |
| J2790 |
Injection, rho d immune globulin, human, full dose, 300 micrograms (1500 i.u.) |
119 |
91 |
$94.38 |
| 84305 |
|
311 |
267 |
$85.74 |
| J7060 |
5% dextrose/water (500 ml = 1 unit) |
329 |
214 |
$84.58 |
| 86039 |
|
145 |
106 |
$81.06 |
| 88175 |
Cytopathology, cervical or vaginal, any reporting system; collected in preservative fluid, automated thin layer |
36 |
25 |
$79.38 |
| 86255 |
|
185 |
136 |
$74.58 |
| 70160 |
|
18 |
17 |
$73.49 |
| 86225 |
|
73 |
52 |
$69.77 |
| 86308 |
|
989 |
753 |
$66.65 |
| G8997 |
Swallowing functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
34 |
26 |
$62.77 |
| 86704 |
|
122 |
97 |
$62.66 |
| 76802 |
|
23 |
17 |
$59.00 |
| J0500 |
Injection, dicyclomine hcl, up to 20 mg |
316 |
244 |
$49.83 |
| 82652 |
|
26 |
13 |
$49.81 |
| 83520 |
|
17 |
13 |
$46.73 |
| 97035 |
|
31 |
13 |
$46.17 |
| G8996 |
Swallowing functional limitation, current status at therapy episode outset and at reporting intervals |
33 |
26 |
$45.50 |
| 86160 |
|
66 |
37 |
$41.82 |
| U0005 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc, making use of high throughput technologies, completed within 2 calendar days from date of specimen collection (list separately in addition to either hcpcs code u0003 or u0004) as described by cms-2020-01-r2 |
1,256 |
482 |
$40.51 |
| 87185 |
|
68 |
53 |
$37.02 |
| 82270 |
|
61 |
48 |
$36.67 |
| A9585 |
Injection, gadobutrol, 0.1 ml |
142 |
119 |
$30.38 |
| P9604 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated trip charge |
615 |
403 |
$30.27 |
| 86141 |
|
126 |
96 |
$25.96 |
| 86147 |
|
20 |
14 |
$24.59 |
| G0145 |
Screening cytopathology, cervical or vaginal (any reporting system), collected in preservative fluid, automated thin layer preparation, with screening by automated system and manual rescreening under physician supervision |
12 |
12 |
$24.46 |
| 82747 |
|
12 |
12 |
$24.23 |
| 86695 |
|
112 |
80 |
$23.72 |
| 94664 |
|
12 |
12 |
$20.61 |
| 89051 |
|
87 |
44 |
$19.88 |
| 72070 |
|
208 |
134 |
$19.84 |
| 85660 |
|
122 |
104 |
$18.70 |
| 84478 |
|
48 |
26 |
$16.27 |
| 84402 |
|
15 |
14 |
$15.89 |
| 99406 |
|
13 |
12 |
$15.67 |
| 80175 |
|
17 |
12 |
$15.16 |
| 82272 |
|
113 |
95 |
$14.43 |
| 83655 |
|
33 |
26 |
$10.67 |
| A9537 |
Technetium tc-99m mebrofenin, diagnostic, per study dose, up to 15 millicuries |
317 |
208 |
$8.74 |
| P9603 |
Travel allowance one way in connection with medically necessary laboratory specimen collection drawn from home bound or nursing home bound patient; prorated miles actually travelled |
169 |
138 |
$8.71 |
| 88108 |
|
329 |
276 |
$8.50 |
| 86735 |
|
16 |
13 |
$6.72 |
| 86765 |
|
16 |
13 |
$6.72 |
| 83930 |
|
37 |
36 |
$4.72 |
| 94644 |
|
177 |
135 |
$4.44 |
| 85362 |
|
95 |
83 |
$1.26 |
| 51798 |
|
53 |
42 |
$0.89 |
| G0328 |
Colorectal cancer screening; fecal occult blood test, immunoassay, 1-3 simultaneous |
146 |
123 |
$0.00 |
| D0272 |
Bitewings - two radiographic images |
35 |
30 |
$0.00 |
| C1768 |
Graft, vascular |
45 |
25 |
$0.00 |
| J2175 |
Injection, meperidine hydrochloride, per 100 mg |
291 |
224 |
$0.00 |
| J3360 |
Injection, diazepam, up to 5 mg |
300 |
172 |
$0.00 |
| D1208 |
Topical application of fluoride, excluding varnish |
99 |
89 |
$0.00 |
| Q3014 |
Telehealth originating site facility fee |
145 |
78 |
$0.00 |
| 0001A |
|
12 |
12 |
$0.00 |
| J2795 |
Injection, ropivacaine hydrochloride, 1 mg |
14 |
12 |
$0.00 |
| 76377 |
|
81 |
39 |
$0.00 |
| L8000 |
Breast prosthesis, mastectomy bra, without integrated breast prosthesis form, any size, any type |
56 |
38 |
$0.00 |
| J2791 |
Injection, rho(d) immune globulin (human), (rhophylac), intramuscular or intravenous, 100 iu |
69 |
61 |
$0.00 |
| 88738 |
|
13 |
12 |
$0.00 |
| D3240 |
|
32 |
24 |
$0.00 |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
24 |
22 |
$0.00 |
| 99205 |
Prolong outpt/office vis |
12 |
12 |
$0.00 |
| D0230 |
Intraoral - periapical each additional radiographic image |
26 |
26 |
$0.00 |
| J1040 |
Injection, methylprednisolone acetate, 80 mg |
52 |
43 |
$0.00 |
| Q9963 |
High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml |
75 |
58 |
$0.00 |
| J1720 |
Injection, hydrocortisone sodium succinate, up to 100 mg |
14 |
13 |
$0.00 |
| 86258 |
|
118 |
60 |
$0.00 |
| 83498 |
|
30 |
25 |
$0.00 |
| 84300 |
|
17 |
12 |
$0.00 |
| 82626 |
|
13 |
12 |
$0.00 |
| 84270 |
|
27 |
25 |
$0.00 |
| 76820 |
|
16 |
12 |
$0.00 |
| 74420 |
|
17 |
12 |
$0.00 |
| 86664 |
|
15 |
12 |
$0.00 |
| 87071 |
|
36 |
26 |
$0.00 |
| 90723 |
|
40 |
12 |
$0.00 |
| J0136 |
Injection, acetaminophen (b braun), not therapeutically equivalent to j0131, 10 mg |
73 |
71 |
$0.00 |
| 31720 |
|
115 |
55 |
$0.00 |
| J2916 |
Injection, sodium ferric gluconate complex in sucrose injection, 12.5 mg |
42 |
16 |
$0.00 |
| D0220 |
Intraoral - periapical first radiographic image |
47 |
44 |
$0.00 |
| J0295 |
Injection, ampicillin sodium/sulbactam sodium, per 1.5 gm |
1,208 |
504 |
$0.00 |
| J0736 |
Injection, clindamycin phosphate, 300 mg |
31 |
31 |
$0.00 |
| J9206 |
Injection, irinotecan, 20 mg |
25 |
12 |
$0.00 |
| 86663 |
|
16 |
13 |
$0.00 |
| J0834 |
Injection, cosyntropin, 0.25 mg |
29 |
28 |
$0.00 |
| 93356 |
|
139 |
98 |
$0.00 |
| 85245 |
|
16 |
12 |
$0.00 |
| 87329 |
|
42 |
29 |
$0.00 |
| 87328 |
|
41 |
26 |
$0.00 |
| 90648 |
|
75 |
56 |
$0.00 |
| J0665 |
Injection, bupivicaine, not otherwise specified, 0.5 mg |
33 |
32 |
$0.00 |
| 83003 |
|
28 |
14 |
$0.00 |
| C1760 |
Closure device, vascular (implantable/insertable) |
51 |
39 |
$0.00 |
| 87336 |
|
38 |
26 |
$0.00 |
| D0350 |
|
15 |
14 |
$0.00 |
| D2940 |
|
40 |
40 |
$0.00 |
| 15853 |
|
22 |
22 |
$0.00 |
| 76376 |
|
16 |
15 |
$0.00 |
| 90675 |
|
27 |
12 |
$0.00 |
| 82042 |
|
34 |
25 |
$0.00 |
| 86235 |
|
25 |
12 |
$0.00 |
| J9000 |
Injection, doxorubicin hydrochloride, 10 mg |
48 |
25 |
$0.00 |
| 86705 |
|
14 |
12 |
$0.00 |
| 87149 |
|
20 |
12 |
$0.00 |
| 62323 |
|
14 |
13 |
$0.00 |